Skip to main navigation menu Skip to main content Skip to site footer
DOI:
https://doi.org/10.57187/5575

Clinical reasoning: Case report

Vol. 156 No. 10 (2026)

Chikungunya case cluster with nonspecific symptoms: implications for primary care in Switzerland

Cite this as:
Swiss Med Wkly. 2026;156:5575
Published
05.10.2026

Summary

BACKGROUND: Early clinical presentation of chikungunya fever and other arbovirus infections is often nonspecific, potentially delaying diagnosis, particularly in settings where these diseases are less frequently considered. Competent vectors are expanding in Switzerland, increasing the risk of autochthonous arbovirus transmission.

CASE SERIES: We report seven cases in a group of travellers returning from Kenya in summer 2025. All patients presented with fever, arthralgia affecting the small joints of the hands and feet, nausea, diarrhoea, and rash. Additional symptoms included generalised lymphadenopathy and peripheral oedema. Initial diagnostic tests were inconclusive, with negative results on rapid diagnostic tests for chikungunya antibodies, dengue antibodies, and malaria antigen. The definitive diagnosis was established after 35 days following the emergence of chikungunya IgG and IgM antibodies.

DISCUSSION: The presentation resembled a nonspecific febrile illness. Repeated, appropriately timed laboratory testing was necessary to establish the diagnosis. Early diagnostic results may be misleading, particularly when testing methods are not selected appropriately for the stage of the disease. With competent mosquito vectors established in Switzerland, imported cases present a risk of local transmission. Severe infections and persistent joint pain may lead to long-term disability.

CONCLUSION: Primary care doctors should consider chikungunya fever in returning travellers and, during the mosquito-active season, in non-travellers in areas with established competent vectors. Patients may present with symptoms ranging from nonspecific febrile illness to more typical manifestations of chikungunya, including fever, arthralgia of the small joints, and rash. Appropriate test selection, timing, and repeated testing when indicated are essential for accurate diagnosis, management, and documentation of the disease.

References

  1. 1. Burt FJ, Chen W, Miner JJ, Lenschow DJ, Merits A, Schnettler E, et al. Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. The Lancet Infectious Diseases. 2017 Apr;17(4):e107-e117. doi:10.1016/S1473-3099(16)30385-1
  2. 2. Federal Office of Public Health FOPH. Massnahmenplan Empfehlungen zur Risikoreduktion von autochthonen Fällen von Dengue, Chikungunya und Zika [Internet]. Bern: ; 2025. Available from: https://www.bag.admin.ch/dam/de/sd-web/0guPUMgqCYOT/Massnahmenplan_Dengue-Chikungunya-Zika_2025_DE.pdf
  3. 3. Weaver SC, Lecuit M. Chikungunya Virus and the Global Spread of a Mosquito-Borne Disease. New England Journal of Medicine. 2015 Mar 26;372(13):1231-1239. doi:10.1056/NEJMra1406035
  4. 4. Appassakij H, Khuntikij P, Kemapunmanus M, Wutthanarungsan R, Silpapojakul K. Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat?. Transfusion. 2013 Oct;53(10pt2):2567-2574. doi:10.1111/j.1537-2995.2012.03960.x
  5. 5. Eckerle I, Briciu VT, Ergönül Ö, Lupşe M, Papa A, Radulescu A, et al. Emerging souvenirs—clinical presentation of the returning traveller with imported arbovirus infections in Europe. Clinical Microbiology and Infection. 2018 Mar;24(3):240-245. doi:10.1016/j.cmi.2018.01.007
  6. 6. Lim A, Shearer FM, Sewalk K, Pigott DM, Clarke J, Ghouse A, et al. The overlapping global distribution of dengue, chikungunya, Zika and yellow fever. Nature Communications. 2025 Apr 10;16(1):3418. doi:10.1038/s41467-025-58609-5
  7. 7. Healthy Travel. Swiss travel recommendations [Internet]. Available from: https://www.healthytravel.ch/de/page?id=0F5705F9-84DE-4951-BC24-F6E266E07572&t=Kenia
  8. 8. Fischer C, Jo WK, Haage V, Moreira-Soto A, de Oliveira Filho EF, Drexler JF. Challenges towards serologic diagnostics of emerging arboviruses. Clinical Microbiology and Infection. 2021 Sep;27(9):1221-1229. doi:10.1016/j.cmi.2021.05.047
  9. 9. WHO. CHIKV global situation [Internet]. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON581
  10. 10. Keny M, Pereira I, deSa S, Gomes E. Painful cervical lymphadenopathy: An unusual presentation of chikungunya. International Journal of Applied and Basic Medical Research. 2014;4(1):47. doi:10.4103/2229-516x.125695
  11. 11. Tong Jia Ming S, Tan Yi Jun K, Carissimo G. Pathogenicity and virulence of O’nyong-nyong virus: A less studied Togaviridae with pandemic potential. Virulence. 2024 Dec 31;15(1):2355201. doi:10.1080/21505594.2024.2355201
  12. 12. Hozé N, Diarra I, Sangaré AK, Pastorino B, Pezzi L, Kouriba B, et al. Model-based assessment of Chikungunya and O’nyong-nyong virus circulation in Mali in a serological cross-reactivity context. Nature Communications. 2021 Nov 18;12(1):6735. doi:10.1038/s41467-021-26707-9
  13. 13. Tegar S, Brass DP, Purse BV, Cobbold CA, White SM. Temperature-sensitive incubation, transmissibility and risk of Aedes albopictus -borne chikungunya virus in Europe. Journal of the Royal Society Interface. 2026 Feb 18;23(235):20250707. doi:10.1098/rsif.2025.0707
  14. 14. Pedí VD, de França GVA, Rodrigues VB, Duailibe FT, Santos MTP, de Oliveira MRF. Burden of Chikungunya Fever and Its Economic and Social Impacts Worldwide: A Systematic Review. Tropical Medicine & International Health. 2025 Sep;30(9):865-892. doi:10.1111/tmi.70012
  15. 15. VACCINATION AGAINST CHIKUNGUNYA – Recommendation of the Swiss Expert Committee for Travel Medicine as of June 2026 [Internet]. Available from: https://www.healthytravel.ch/de/gt-fl?attachment_id=Mzc4Nw%3D%3D&t=UERGNQ%3D%3D&download_file=Chikungunya_Vaccination_Statement_HCW_ECTM_EN_2025_11_06.pdf

Most read articles by the same author(s)

1 2 > >>